These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 18474286)

  • 1. The role of antiarrhythmic drug therapy for the prevention of sudden cardiac death.
    Kamath GS; Mittal S
    Prog Cardiovasc Dis; 2008; 50(6):439-48. PubMed ID: 18474286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of concomitant antiarrhythmic therapy on survival in patients with implantable cardioverter defibrillators.
    Ho AT; Pai SM; Timothy P; Pai RG
    Pacing Clin Electrophysiol; 2005 Jul; 28(7):647-53. PubMed ID: 16008799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiarrhythmic and nonantiarrhythmic drugs for sudden cardiac death prevention.
    Das MK; Zipes DP
    J Cardiovasc Pharmacol; 2010 May; 55(5):438-49. PubMed ID: 20509177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiarrhythmic drugs in patients with implantable cardioverter-defibrillators.
    Bollmann A; Husser D; Cannom DS
    Am J Cardiovasc Drugs; 2005; 5(6):371-8. PubMed ID: 16259525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arrhythmogenic right ventricular cardiomyopathy. Antiarrhythmic drugs, catheter ablation, or ICD?
    Wichter T; Paul TM; Eckardt L; Gerdes P; Kirchhof P; Böcker D; Breithardt G
    Herz; 2005 Mar; 30(2):91-101. PubMed ID: 15875097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of antiarrhythmic drugs: frequent implantable cardioverter-defibrillator shocks, risk of proarrhythmia, and new drug therapy.
    Droogan C; Patel C; Yan GX; Kowey PR
    Heart Fail Clin; 2011 Apr; 7(2):195-205, viii. PubMed ID: 21439498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A guide to device selection: cardiac resynchronization therapy alone or in combination with an implantable cardioverter defibrillator.
    Prystowsky EN
    Rev Cardiovasc Med; 2003; 4 Suppl 2():S47-54. PubMed ID: 12776013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of antiarrhythmic therapy in patients at risk for sudden cardiac death: an evidence-based review.
    Hilleman DE; Bauman AL
    Pharmacotherapy; 2001 May; 21(5):556-75. PubMed ID: 11349745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implantable device therapy.
    Goldenberg I; Moss AJ
    Prog Cardiovasc Dis; 2008; 50(6):449-74. PubMed ID: 18474287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implantable cardioverter defibrillator therapy and the need for concomitant antiarrhythmic drugs.
    Singh S; Murawski MM
    J Cardiovasc Pharmacol Ther; 2007 Sep; 12(3):175-80. PubMed ID: 17875944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sudden cardiac death: who needs an implantable cardioverter-defibrillator and who needs antiarrhythmic drugs?
    Ferrari R; Cinca J; Marber M
    Eur Heart J; 1999 Mar; 20(6):397-8. PubMed ID: 10213339
    [No Abstract]   [Full Text] [Related]  

  • 12. [Pharmacologic therapy of ventricular tachyarrhythmias: value of class III anti-arrhythmia drugs].
    Haverkamp W; Borggrefe M; Block M; Böcker D; Breithardt G
    Z Kardiol; 1996; 85 Suppl 6():97-106. PubMed ID: 9064989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can we predict sudden cardiac death in long-term survivors of atrial switch surgery for transposition of the great arteries?
    Wheeler M; Grigg L; Zentner D
    Congenit Heart Dis; 2014; 9(4):326-32. PubMed ID: 24151816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Should catheter ablation be the preferred therapy for reducing ICD shocks?: Ventricular tachycardia ablation versus drugs for preventing ICD shocks: role of adjuvant antiarrhythmic drug therapy.
    Patel C; Yan GX; Kocovic D; Kowey PR
    Circ Arrhythm Electrophysiol; 2009 Dec; 2(6):705-11; discussion 712. PubMed ID: 20009081
    [No Abstract]   [Full Text] [Related]  

  • 15. The Midlands Trial of Empirical Amiodarone versus Electrophysiology-guided Interventions and Implantable Cardioverter-defibrillators (MAVERIC): a multi-centre prospective randomised clinical trial on the secondary prevention of sudden cardiac death.
    Lau EW; Griffith MJ; Pathmanathan RK; Ng GA; Clune MM; Cooper J; Marshall HJ; Forsey PR; Stafford PJ; Gray RG; Skehan JD; Garratt CJ
    Europace; 2004 Jul; 6(4):257-66. PubMed ID: 15172648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delayed and indirect effects of antiarrhythmic drugs in reducing sudden cardiac death.
    Malhotra S; Das MK
    Future Cardiol; 2011 Mar; 7(2):203-17. PubMed ID: 21453027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Primary prevention of sudden cardiac death implanted cardioverter defibrillator (ICD) versus antiarrhythmic drugs].
    Iturralde Torres P
    Arch Cardiol Mex; 2007; 77 Suppl 4():S4-129-32. PubMed ID: 18938711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can antiarrhythmic drugs survive survival trials?
    Pratt CM; Waldo AL; Camm AJ
    Am J Cardiol; 1998 Mar; 81(6A):24D-34D. PubMed ID: 9537220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of sudden cardiac death.
    Goldberger JJ
    Heart Dis; 2000; 2(4):305-13. PubMed ID: 11728274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Frequent ventricular tachycardias: antiarrhythmic drug treatment or catheter ablation?].
    Tanner H; Hindricks G; Kottkamp H
    Herz; 2005 Nov; 30(7):613-8. PubMed ID: 16333587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.